Tot Biopharm Company Limited, a Suzhou, China-based bio-pharmaceutical company specializing in developing, manufacturing and commercializing oncology drugs, completed a US$102m Series B financing round.
The round was supported by China Universal (Cayman) GP Limited and several domestic and foreign investors, as well as investors who had participated in earlier rounds, including Center Laboratories Group, Vivo Capital, Chengwei Capital, Yuanta Financial Holdings Group and Cathay Capital.
Led by general manager Gloria Huang, Tot Biopharm focuses on the R&D, manufacturing and marketing of anti-tumor drugs. The company now has over 10 drugs in the R&D stage, including three biologics and three small molecules, which have received investigational new drug application (IND) approvals, as well as one antibody-drug conjugate (ADC), which is expected to receive approval soon.
Tot Biopharm intends to use the funds to continue to accelerate development of its key pipelines.
The company recently announced results of the Phase I clinical trial (double-blind, head-to-head pharmacokinetics and safety comparisons) of Bevacizumab biosimilar, TAB008, which is now in Phase III clinic trial. The IND application for TAA013, an ADC, is currently in the review process. Tot Biopharm is also in the process of ramping up production of its third-generation innovative oncolytic virus drug TVP211.